Type II (non-insulin-dependent) diabetes mellitus is characterised by insulin resistance and decreased insulin secretion from pancreatic beta cells [1] . The increase of cytosolic Ca 2+ in the beta cell is central to the initiation of insulin secretion under physiological conditions. The proteins involved in the regulation of calcium in the islet beta cell are candidate genes for Type II diabetes. There is substantial evidence to show that Ca 2+ /calmodulin-dependent protein kinase II (CaMK II) plays a role in calcium regulation of insulin secretion [2] . CaMK II is a ubiquitous serine/ threonine protein kinase with a broad substrate spec- Diabetologia (2002) /calmodulin-dependent protein kinase II mediates some of the actions of Ca 2+ on the exocytosis of insulin. We therefore investigated the gene encoding the gamma isoform (CAMK2G) which has been shown to be expressed in human beta cells as a candidate gene for Type II (non-insulin-dependent) diabetes mellitus. Methods. Human CAMK2G was cloned from a total human P1 artificial chromosome library using a partial Ca 2+ /calmodulin-dependent protein kinase g E cDNA probe. Positive PAC clones were localised to chromosome 10q22 by fluorescence in situ hybridisation. To obtain structural information and the sequences of the exon±intron boundaries, the published genomic structures of the rat and mouse genes allowed the putative exon-intron boundaries of human CAMK2G to be amplified by vectorette polymerase chain reaction and sequenced. Sequence variants in each exon were identified using single stranded conformational polymorphism analysis. Results. The human CAMK2G gene comprises 22 exons which range in size between 43 to 230 bp. Screening of the exons and exon±intron boundaries identified two single nucleotide polymorphisms. These did not show association with diabetes in 122 patients and 144 control subjects. Conclusions/interpretation. We have identified the genomic structure of CAMK2G to enable further study of this potential candidate gene. Variation in this gene is not strongly associated with diabetes in Caucasians in the United Kingdom. We have identified two single nucleotide polymorphisms which, with appropriately large case control studies, can be used to assess the role of CAMK2G in the susceptibility to Type II diabetes. [Diabetologia (2002) 45: 580±583] 
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Screening of a human islet cDNA library identified two distinct g isoforms of CaMK II g E and g B [4] . The entire CaMK II g E cDNA nucleotide and predicted amino acid sequence has been obtained from two identified overlapping clones. Recently other isoforms of CaMK II in the human beta cell have been determined [5] . The authors reported expression of isoforms of CaMK II b, d, and g. Although CaMK II g mRNA was identified, the degree of expression was low [5] . Given that CaMK II exists as both a heteromultimer and a homomultimer the composition of this enzyme is critical for its cell-specific function. Even isoforms expressed at low amounts in the beta cell could be critical for the correct intracellular targeting of the heteromultimer. To date none of the members of this multigene family have been screened for variants in patients with Type II diabetes. Therefore, we determined the exon-intron structure of the CaMK II g gene (CAMK2G) and screened the exons and exon-intron junctions for variants in patients with Type II diabetes.
Subjects and methods
Isolation of human genomic clones and DNA sequencing. The CAMK2G gene was cloned from a total HPAC library. The library was made available by Dr. R. Cox of the Wellcome Trust Centre for Human Genetics (Oxford, UK) and was screened with partial CaMK II g E cDNA (Genbank accession No. U66 064) using a standard protocol.
Chromosomal localisation and detection of chimerisim was carried out by fluorescence in situ hybridisation (FISH) of metaphase arrested spreads of human chromosomes to the PAC DNA. EBV-immortalised normal male lymphoblastoid cell lines were harvested by conventional techniques and fixed suspensions were dropped onto slides. Fluorescence in situ hybridisation of PACs was carried out as previously described [6] . The chromosome 10 specific centromeric probe D10Z1DG.5 was purchased labelled with digoxigenin (Appligene Oncor, Harefield, UK).
Exon/intron boundaries for exons 5±8 and 14±19 were identified by homology of the reported cDNA sequence (Genbank accession No. U66 063 and U66 064) with the genomic structures of the rat [7] and mouse [8] camk2a and camk2b isoforms respectively. Exon-intron boundaries were amplified and sequenced by vectorette PCR [9] . Polymerase chain reaction amplified products were sequenced on an automated ABI 377 DNA sequencer with dye terminator chemistry (Applied Biosystems, Warrington, UK). The boundaries of the remaining exons were determined by comparing the reported cDNA sequences for human CaMK II g E and rat CaMK II g A (Genbank accession number J04 063) to a contig in the human genome project chromosome 10 data base which was identified by BLAST homology searches (Genbank accession numbers AC073 372 and AC022 400).
Subjects. The screening for variants in the gene encoding calcium/calmodulin protein kinase II gamma (CAMK2G) was carried out in 76 subjects with Type II diabetes randomly selected from the United Kingdom Prospective Diabetes Study (UKPDS) cohort (58 % men, age 50.7 7.8 years, BMI 27.7 5.3 kg/m 2 , fasting plasma glucose 8.2 mmol/l IQR 7.2±10.9, fasting insulin 85pmol/l IQR 47±152, beta-cell function calculated by HOMA analysis was 49 % IQR 28±84, HbA 1 c 7.0 % IQR 6.0±8.2, percentage family history of diabetes was ascertained to be 35 %, all values at the time of diagnosis). Of the patients 19 had severe beta-cell dysfunction as defined by a HOMA value of less than 28 % of normal young adults. An additional group of 46 diabetic subjects randomly selected from the UKPDS with similar characteristics was used for genotyping of identified variants. The control population consisted of 144 normoglycaemic subjects without a family history of diabetes randomly selected from the Diabetes in Families study (DIF) (BMI 25.7 5.1 kg/m 2 , fasting plasma glucose 5.3 5.0±5.6 mmol/l, beta-cell function ascertained by HOMA, 100 77±130 %). Both cohorts were of similar age and from the same geographical region. All subjects gave their informed consent in accordance with the Declaration of Helsinki as revised in 1996.
SNP identification and genotyping. Polymerase chain reaction primers were designed to amplify the exons and intronic flanking regions of the CAMK2G gene. To ensure accurate determination of the exon-intron boundaries the exons were amplified and re-sequenced from DNA of CEPH individual 134 702. Primers were designed to encompass the maximum amount of intronic sequence possible, given the restrictions on PCR fragment size for SSCP, to include putative branch sites in addition to the splice sites. All PCR primers and amplification conditions are available from the authors on request. Single stranded conformational polymorphism (SSCP) analysis was carried out using fluorescently labelled PCR products run on a 25 % MDE gel (Flowgen, Lichfield, UK) using an ABI 377 automated DNA sequencer (Applied Biosystems).
In addition to SSCP screening, exons 13±22, which encode for the variable domains were sequenced directly in both directions for five DNA Type II diabetic patients selected at random. All sequencing was carried out on an automated ABI377 DNA sequencer with dye terminator chemistry (Applied Biosystems).
The genotype and allele frequencies of the exon 2 (K49 K) variant were determined in 122 diabetic subjects, including an additional 46 Type II diabetic subjects and control subjects matched for age from the DIF study (n = 144) by restriction fragment length polymorphism analysis (RFLP) with the restriction enzyme Tsp EI (Promega, Southampton, UK). Digested PCR products were separated by standard agarose electrophoresis.
Statistical analysis. Associations between the polymorphic exon 2 marker in the CAMK2G gene with Type II diabetes were evaluated by chi-square analysis. A p value of less than 0.05 was considered statistically significant. To assess linkage disequilibrium (LD) between the two loci haplotype frequencies were calculated using the maximum likelihood output from the estimated haplotype program [10] .
Results
Isolation and characterisation of the human CAMK2G gene. Screening of a HPAC library using a partial CaMK II g e cDNA probe identified six positive clones. All six clones were shown to be contiguous and localisation was confirmed as chromosome 10q22 by FISH. Using the published structure of the homologous rat and mouse CaMK II genes the putative exon-intron boundaries of CAMK2G were elucidated. Amplification of positive PAC clones by vectorette PCR enabled sequencing of the unknown intron-exon boundaries of the gene. By this method the exon-intron boundaries of exons 2±8 and 14±19 were determined. Large intronic regions between the remaining exons meant that genome walking was laborious. During the study two contigs appeared in the human genome project chromosome 10 database which were identified by BLAST homology searches as containing the CAMK2G gene (Genbank accession numbers AC073 372 and AC022 400). Comparison of the reported cDNA sequences for human cam kinase II g E and rat cam kinase II g A enabled completion of the genomic structure except for exon 1, which was not contained within the contig. Human CAMK2G contains 22 exons that are 43±230 bp in length (Genbank accession numbers AF415177-AF415 198 inclusive). The size and position of the exons and 3'UTR of the CAMK2G gene are summarised (Table 1) . Prior to screening, the exons were amplified and sequenced in a CEPH individual to confirm the accurate amplification of each exon from the boundaries determined. Sequencing of the CAMK2G gene exons in this individual confirmed the correct determination of the exon-intron boundaries. Comparison of the genomic structure of human CAMK2G to the published rodent isoforms showed a high degree of conservation for the exons encoding the catalytic (exons 1±10) and regulatory domains (exons 11±13) of the enzyme.
Screening of CAMK2G and SNP Identification. Two variants were detected; in exon 2 the silent polymorphism, (K49K) AAG → AAA and an intronic variant, exon 14 (+ 58 c→ t). Mutation detection by direct sequencing in addition to SSCP for the exons encoding the variable domains of the protein ensured excellent detection sensitivity. Despite this, no additional variants were detected. A small preliminary casecontrol study of 122 patients and 144 control subjects showed no association of the exon 2 variant with diabetes (p = 0.86) ( Table 2 ). The frequency of the intronic variant (exon 14 + 58 c → t) in the 76 Type II diabetic subjects was cc 0.35, ct 0.54, tt 0.11. Haplotype analysis of the two loci detected almost perfect LD between the exon 2 and exon 14 variant, (c 2 = 132.35, p < 0.001). Exon 1 could not be determined due to the fact the contig identified from the database did not contain the sequence, and genome walking by vectorette PCR was not possible due to the large size of intron 1. For exons with alternate splice sites the sizes of both splice variants are given. The 3'untranslated region (3'UTR) is also listed. Genomic structure Genbank accession numbers AF415177-AF415198
Discussion
Comparison of the genomic structure of human CAMK2G to the published rodent isoforms showed a high degree of conservation for the exons encoding the catalytic and regulatory domains of the enzyme [7±8]. Screening of these exons and their flanking intronic regions only identified a silent variant in the catalytic domain of the protein and an intronic variant. These SNPs are not likely to be pathogenic and can only be used to assess other pathogenic non-coding variants that are in linkage disequilibrium. Both variants have allele frequencies greater than 10 % which makes them suitable for large scale family±based association studies to determine the role of CAMK2G in the susceptibility to Type II diabetes [11] .
In conclusion, we have determined the exon-intron organisation of the CAMK2G gene and showed that it consists of 22 exons. We have failed to identify common coding variants in Caucasians in the United Kingdom. This does not exclude rare variants in this population or common variants in other races. Severe mutation in this gene or other members of the multigene family might cause MODY by causing marked beta-cell dysfunction.
